Toronto Dominion Bank Has $1.77 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Toronto Dominion Bank raised its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 51.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,080 shares of the company's stock after purchasing an additional 9,151 shares during the period. Toronto Dominion Bank's holdings in AstraZeneca were worth $1,774,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Cibc World Markets Corp boosted its holdings in AstraZeneca by 1.1% in the 4th quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock valued at $845,000 after purchasing an additional 142 shares during the period. CoreCap Advisors LLC lifted its holdings in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock worth $42,000 after acquiring an additional 155 shares during the period. Tiller Private Wealth Inc. lifted its holdings in shares of AstraZeneca by 5.7% during the 4th quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company's stock worth $219,000 after acquiring an additional 181 shares during the period. Dorsey & Whitney Trust CO LLC lifted its holdings in shares of AstraZeneca by 0.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company's stock worth $2,313,000 after acquiring an additional 189 shares during the period. Finally, Pine Valley Investments Ltd Liability Co lifted its holdings in shares of AstraZeneca by 3.3% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 5,995 shares of the company's stock worth $393,000 after acquiring an additional 190 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Price Performance

AZN stock traded up $1.18 during trading on Wednesday, hitting $73.00. 3,620,695 shares of the stock traded hands, compared to its average volume of 5,195,274. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The stock has a market cap of $226.39 billion, a price-to-earnings ratio of 32.30, a P/E/G ratio of 1.42 and a beta of 0.38. The company has a 50 day simple moving average of $69.33 and a 200 day simple moving average of $69.83. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm posted $2.06 EPS. Equities analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. BNP Paribas assumed coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. Finally, Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.